Zhenyu Xu Sells 2,700 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 2,700 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $4.85, for a total transaction of $13,095.00. Following the completion of the sale, the insider owned 647,352 shares in the company, valued at approximately $3,139,657.20. This trade represents a 0.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Tuesday, April 7th, Zhenyu Xu sold 2,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $11,688.00.
• On Thursday, March 19th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.78, for a total transaction of $2,906.24.

SOPHiA GENETICS Price Performance

Shares of SOPHiA GENETICS stock opened at $4.73 on Friday. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The company’s 50-day moving average price is $4.76 and its two-hundred day moving average price is $4.68. SOPHiA GENETICS SA has a 52 week low of $2.58 and a 52 week high of $5.70. The stock has a market cap of $323.96 million, a PE ratio of -9.27 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The business had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. As a group, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large institutional buying: UBS Asset Management and Akre Capital materially increased positions recently (UBS added ~5.4M shares). That sizable institutional demand can support the stock and offsets some insider selling. MarketBeat Institutional/Insider Summary
• Neutral Sentiment: Multiple senior executives (CEO Jurgi Camblong, CFO George Cardoza, CTO Abhimanyu Verma, President Ross Muken and others) executed several small sales (roughly 600–2,700 shares each) under Rule 10b5‑1 plans to cover tax withholding tied to vesting awards; these are disclosed in SEC Form 4 filings. Representative SEC filing (CEO): CEO Form 4
• Neutral Sentiment: Analyst views are mixed but skew positive: Guggenheim and BTIG have reiterated/raised targets to ~$7 with buy ratings, while one service retains a sell. Those analyst targets imply upside vs. current levels and help explain why institutional buyers remain active. Analyst Coverage
• Negative Sentiment: Collective insider selling can create short‑term downward pressure — even though each trade is small and pre‑arranged, the clustered timing (multiple execs selling within the same days) contributed to intraday selling and likely drove the price lower. Summary of the insider trade reports: InsiderTrades article

Analyst Upgrades and Downgrades

Several research firms have issued reports on SOPH. BTIG Research restated a “buy” rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Guggenheim boosted their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $7.00.

Institutional Trading of SOPHiA GENETICS

Institutional investors and hedge funds have recently bought and sold shares of the stock. Alta Wealth Advisors LLC acquired a new stake in SOPHiA GENETICS during the 3rd quarter worth about $6,708,000. Dimensional Fund Advisors LP raised its holdings in SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after buying an additional 6,205 shares during the period. Polen Capital Management LLC acquired a new stake in SOPHiA GENETICS during the 4th quarter worth about $102,000. XTX Topco Ltd acquired a new stake in SOPHiA GENETICS during the 4th quarter worth about $55,000. Finally, Quadrature Capital Ltd acquired a new stake in SOPHiA GENETICS during the 4th quarter worth about $54,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.